Results from 3 randomized and quasi-randomized controlled trials (n=573) indicate that giving phenobarbitone routinely to people with cerebral malaria reduces the number of convulsions, but may increase the risk of death.
This Evidence Update was adapted from Meremikwu M, Marson AG. Routine anticonvulsants for treating cerebral malaria (Cochrane Review). In: The Cochrane Library, Issue 3, 2003.
Malaria Series, Effective Health Care Alliance Programme, Liverpool School of Tropical Medicine, 2 pp.